New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform as a Targeted Drug-Delivery Approach Data Shows a PK Profile that May Improve Clinical Efficacy and Decrease Clinical Side Effects with TAMP and Intra-Arterial Gemcitabine Versus Standard of Care Chemotherapy MOUNTAIN VIEW, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing ...